Glaxo Licensing Deal Signals Confidence In Electrical Drug Delivery Treatment
This article was originally published in The Gray Sheet
Executive Summary
Transport Pharmaceuticals intends to launch a 600-patient, Phase III study of its iontophoretic drug delivery device the week of March 1 to support European market go-ahead by early 2006